This EPPV study provides safety information for a 6-month period after the administration of encorafenib and binimetinib in Japanese patients with advanced BRAF V600E-mutated colorectal cancer, which is the first real-world safety data of the triplet and doublet regimens for colorectal cancer. This evidence concerns the gene BRAF and colorectal cancer.